GB9413975D0 — New heterobicyclic derivatives
Assigned to Fujisawa Pharmaceutical Co Ltd · Expires 1994-08-31 · 32y expired
What this patent protects
Heterobicyclic derivatives of formula (I) wherein R<1> is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl wh…
USPTO Abstract
Heterobicyclic derivatives of formula (I) wherein R<1> is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R<2> is aryl which may have suitable substituent(s) or heterocyclic group, and R<3> is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as PDE IV and TNF inhibitors for the treatment of hepatitis in human beings and animals. <CHEM>
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.